Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.45 |
| ▸ | CCKBR | P32239 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24235647 | 1.00 | ACE (0.54) | ACEKMT2AALDH1A1MEN1HPGD | |
| SCHEMBL23475261 | 0.94 | MEN1 (0.50) | ACEKMT2AALDH1A1MEN1HPGD | |
| SCHEMBL18196507 | 0.90 | FOLH1 (0.50) | ACEKMT2AALDH1A1MEN1HPGD | |
| SCHEMBL19401695 | 0.90 | ACE (0.51) | ACEKMT2AALDH1A1MEN1HPGD | |
| SCHEMBL20322999 | 0.90 | ACE (0.51) | ACEKMT2AALDH1A1MEN1HPGD | |
| SCHEMBL10825301 | 0.90 | ACE (0.51) | ACEKMT2AALDH1A1MEN1HPGD | |
| SCHEMBL24983660 | 0.89 | KMT2A (0.50) | ACEKMT2AALDH1A1MEN1HPGD | |
| SCHEMBL28713376 | 0.89 | KMT2A (0.50) | ACEKMT2AALDH1A1MEN1HPGD | |
| SCHEMBL24235727 | 0.89 | MEN1 (0.52) | ACEKMT2AALDH1A1MEN1HPGD | |
| SCHEMBL13416240 | 0.88 | KMT2A (0.56) | ACEKMT2AALDH1A1MEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6436691-B1 | CONJUGATE WHICH IS SUBSTANTIALLY NON-IMMUNOGENIC IN HUMANS COMPRISING TARGETING MOIETY CAPABLE OF BINDING WITH TUMOR ASSOCIATED ANTIGEN LINKED TO MUTATED FORM OF CARBOXYPEPTIDASE B ENZYME CAPABLE OF CONVERTING PRODRUG INTO ANTICANCER DRUG | ZENECA LIMITED (GB) | 2002-08-20 | — | — | US | disclosed |
| US-5985281-A | ANTIBODY DIRECTED ENZYME PRODRUG THERAPY (ADEPT) USING A NON-NATURALLY OCCURING MUTANT FORM OF A HOST ENZYME, ESPECIALLY A MUTANT FORM OF RIBONUCLEASE. | ZENECA LIMITED (GB) | 1999-11-16 | — | — | US | disclosed |